Fultagliptin Benzoate

苯甲酸福格列汀

Report date: 2025/11/21 16:16:22
NME

Base Information

Drug NameFultagliptin Benzoate
Drug Alias NameFutagliptin benzoic acid苯甲酸复格列汀Fotagliptin信立汀FCN-005 +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDipeptidyl peptidase IV inhibitors
TargetsDipeptidyl peptidase IV
Therapy Area/IndicationsDiabetes Mellitus, Type 2Renal Insufficiency
Global Approved IndicationsDiabetes Mellitus, Type 2
Approved Indications in ChinaDiabetes Mellitus, Type 2
Original Approved Country/TerritoryMainland China
Original Approved Date2024/06/28
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesFochon Pharmaceuticals LtdShanghai Fosun Pharmaceutical (Group) Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesShenzhen Salubris Pharmaceuticals Co Ltd
Inactive CompaniesFochon Pharmaceuticals LtdHuizhou Xinlitai Pharmaceutical Co Ltd
Active IndicationsDiabetes Mellitus, Type 2Renal Insufficiency
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A